Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: Ii-Key peptide hybrid vaccines - NuGenerex Immuno-Oncology

Next Previous
Drug Profile

Research programme: Ii-Key peptide hybrid vaccines - NuGenerex Immuno-Oncology

Alternative Names: AEH10p; HPV vaccine - NuGenerex Immuno-Oncology; Human papillomavirus vaccine - NuGenerex Immuno-Oncology; Ii-Key/GAD; Ii-Key/HPV16 E7; Ii-Key/insulin; Ii-Key/MHC

Latest Information Update: 16 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Antigen Express
  • Developer Antigen Express; NuGenerex Immuno-Oncology
  • Class Cancer vaccines; Diagnostic agents; Viral vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical HIV infections; Human papillomavirus infections; Hypersensitivity; Influenza virus infections; Type 1 diabetes mellitus
  • Discontinued Smallpox

Most Recent Events

  • 08 Feb 2017 Human papillomavirus vaccine is still in preclinical development for Human papillomavirus infections in USA (Antigen Express pipeline, February 2017)
  • 07 Feb 2013 Antigen Express is considering partnerships to develop novel Ii-Key peptide hybrid vaccines as of 07 Feb 2013. http://www.antigenexpress.com/
  • 20 Apr 2009 Pharmacodynamics data from a preclinical trial in cancer presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top